Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,816 across all filing types
Latest filing 2024-04-22 Transaction in Own Shar…
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Transactions in Connection with Share Buy-back Program Genmab
Transaction in Own Shares Classification · 1% confidence The document is a formal company announcement detailing specific transactions executed under a share buy-back program. It provides a table of daily share repurchases, average prices, and total values, and explicitly states the impact on treasury shares. This aligns perfectly with the definition of 'Transaction in Own Shares' (POS).
2024-04-22 English
Transactions in Connection with Share Buy-back Program Genmab
Transaction in Own Shares Classification · 1% confidence The document is a company announcement detailing specific transactions executed under a share buy-back program. It provides a table of daily share repurchases, total shares held as treasury shares, and references the regulatory framework (MAR/Safe Harbour). Since the document reports on the company buying back its own shares, it falls under the 'Transaction in Own Shares' category.
2024-04-22 Danish
6-K
Foreign Filer Report
2024-04-16 English
Earnings Release 2024
Earnings Release Classification · 1% confidence The document is titled "Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024" and provides key financial highlights (net sales figures) for a specific fiscal period (Q1 2024). This structure—a brief announcement focusing on key performance indicators for a recent period without the full detail of a comprehensive report—is characteristic of an Earnings Release (ER). It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR), but rather the initial public announcement of the results. Q1 2024
2024-04-16 English
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024
Earnings Release Classification · 1% confidence The document is a short company announcement (Company Announcement no. 29) regarding the net sales of a specific product (DARZALEX) for the first quarter of 2024. It explicitly includes an 'Attachment' link at the bottom, which is a hallmark of a Report Publication Announcement (RPA). It is not a full quarterly report (IR) or earnings release (ER) itself, but rather a notification of the sales data release. Q1 2024
2024-04-16 Danish
6-K
Foreign Filer Report
2024-04-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.